Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Assets Average (2020 - 2025)

Nurix Therapeutics (NRIX) has disclosed Assets Average for 6 consecutive years, with $605.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average rose 2.34% to $605.3 million in Q4 2025 year-over-year; TTM through Nov 2025 was $605.3 million, a 2.34% increase, with the full-year FY2025 number at $678.7 million, up 32.44% from a year prior.
  • Assets Average was $605.3 million for Q4 2025 at Nurix Therapeutics, up from $557.0 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $642.2 million in Q1 2025 to a low of $329.4 million in Q3 2023.
  • A 5-year average of $462.8 million and a median of $447.6 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: decreased 24.23% in 2023, then soared 92.2% in 2025.
  • Nurix Therapeutics' Assets Average stood at $484.9 million in 2021, then dropped by 9.67% to $438.0 million in 2022, then dropped by 24.23% to $331.9 million in 2023, then soared by 78.21% to $591.5 million in 2024, then increased by 2.34% to $605.3 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Assets Average are $605.3 million (Q4 2025), $557.0 million (Q3 2025), and $603.3 million (Q2 2025).